Status:
COMPLETED
Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER
Lead Sponsor:
ThermoFisher Scientific Brahms Biomarkers France
Collaborating Sponsors:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the ...
Detailed Description
Acute exacerbation of COPD (AECOPD)are usual and frequent cause of admission in emergency room (ER). No validated clinical or biological predictor of evolution are available. The main objective is to...
Eligibility Criteria
Inclusion
- patients \> 40 years old
- Acute exacerbation of COPD
Exclusion
- Medico social conditions not allowing home discharge
- Other causes of Dyspnea: Pneumothorax, pulmonary embolism, pulmonary oedema, lung cancer
- Pneumonia on chest ray
- acute respiratory distress requiring immediate ICU transfer
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT01857947
Start Date
March 1 2013
End Date
December 1 2014
Last Update
December 3 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Lariboisière
Paris, Paris, France, 75010
2
Pitié Salpétrière Hospital
Paris, Paris, France, 75013